Biotechnology New overall survival (OS) Phase III data, showing that Trodelvy (sacituzumab govitecan-hziy) significantly reduced the risk of death for people with triple-negative breast cancer (TNBC) by 52%, with a mean OS of 12.1 months compares to 6.7 months for standard single-agent chemotherapy, were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. 21 September 2020